Testing ARI0003 cells for aggressive B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early study tests a new cell therapy called ARI0003 for people with certain aggressive B-cell lymphomas not cured by standard treatments. The goal is to see if this therapy can help when other options fail.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma that has come back or not responded to treatment (like Burkitt's lymphoma or other rare forms not covered by standard CAR T-cell therapies).
- Your tumor must carry at least one of two specific markers on its surface called CD19 or CD269.
- You should be 18 years of age or older.
- You must be able to function fairly independently (need help only for daily activities less than half of the day).
- If you have received a previous anti-CD19 or anti-CD269 treatment, the study needs a sample of your tumor to confirm that it still carries one of those markers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of immune cell that targets two markers (CD19 and CD22) on lymphoma cells. It is for patients whose lymphoma has come back or not responded after at least two prior treatments.
This trial is testing a new cell therapy called ARI0002h for people newly diagnosed with primary plasma cell leukemia, an aggressive type of multiple myeloma. It aims to see if the treatment is safe and effective as an initial therapy.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
Hear when a new Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.